dual orexin receptor GPCR antagonist
Ph. III efficacy for insomnia, oral 25-50 mg
from optimization of prior clinical candidate
ChemMedChem., Oct. 28, 2020
Idorsia Pharmaceuticals, Allschwil, CH
daridorexant
Idorsia clinical dual orexin receptor GPCR antagonist